Peptide News Digest

#Biased-Agonism

3 stories

Industry · View digest

Chinese Biotech GLP-1 Ecnoglutide Post-Lancet Publication Follow-Through: Xianweida's cAMP-Biased Agonist Continues Global-Launch Positioning

Following the August 22 Lancet Diabetes & Endocrinology publication of the full EECOH-2 Phase 3 trial results for Xianweida's ecnoglutide (XW003, a first-in-class cAMP-biased GLP-1 receptor agonist that preferentially activates the cAMP signaling pathway over β-arrestin recruitment), Chinese biotech peptide activity continued through end of August into September. Ecnoglutide received its Chinese NMPA approval for type 2 diabetes January 30, 2026, followed by the March 6, 2026 approval for weight management in adults with overweight or obesity; the Lancet publication supplies the peer-reviewed data package supporting global regulatory submissions. Ecnoglutide is licensed to Pfizer under the up-to-$495 million partnership announced in 2024 for ex-China commercialization. The biased-agonism concept (selective signaling pathway activation to separate efficacy from tolerability) is now being pursued by CSPC (SYH2069 GLP-1/GIP dual-biased agonist) and other Chinese biotech peptide developers.

Clinical Trials · View digest

The Lancet Diabetes & Endocrinology Published Saturday August 22, 2026 the Full EECOH-2 Phase 3 Trial Results for Xianweida's Ecnoglutide (XW003), a First-in-Class cAMP-Biased GLP-1 Receptor Agonist That Preferentially Activates the cAMP Signaling Pathway Over β-Arrestin Recruitment; The 52-Week Open-Label Non-Inferiority Trial Across 52 Chinese Hospitals Compared Ecnoglutide (0.6 mg or 1.2 mg Once Weekly Subcutaneous Injection) Against Dulaglutide 1.5 mg in Adults With Type 2 Diabetes and Elevated Glucose Concentrations on Metformin Monotherapy; Both Ecnoglutide Doses Met the Non-Inferiority Endpoint on HbA1c Reduction, and Both Were Well Tolerated; The Biased-Agonism Concept (Selective Signaling Pathway Activation Rather Than Full Receptor Engagement) Has the Potential to Separate Efficacy From Side Effects in the GLP-1 Class

The Lancet Diabetes & Endocrinology published Saturday August 22, 2026 the full EECOH-2 Phase 3 trial results for Xianweida's ecnoglutide (XW003), a first-in-class cAMP-biased GLP-1 receptor agonist. Mechanism: ecnoglutide preferentially activates the cAMP intracellular signaling pathway over β-arrestin recruitment when it binds the GLP-1 receptor. This biased-agonism concept selects one downstream signaling arm over the other, with the theoretical potential to separate the therapeutic effects (glucose lowering via cAMP-mediated insulin secretion) from the side-effect burden (some of which may be β-arrestin-mediated). Trial design: 52-week open-label non-inferiority Phase 3 across 52 Chinese hospitals. Adults aged 18-75 years with BMI 20-35 kg/m2, type 2 diabetes diagnosis, and elevated glucose concentrations on metformin monotherapy. Randomized to subcutaneous ecnoglutide 0.6 mg or 1.2 mg once weekly, or dulaglutide 1.5 mg once weekly (active comparator). Primary results: both ecnoglutide doses met the non-inferiority endpoint on HbA1c reduction versus dulaglutide 1.5 mg. Both doses were well tolerated with a safety profile broadly consistent with the GLP-1 receptor agonist class. Ecnoglutide is the first global cAMP-biased GLP-1 receptor agonist to reach Phase 3 publication. The biased-agonism approach could inform next-generation GLP-1 drug design and offers a differentiated tolerability profile if the concept holds in larger populations.

Clinical Trials · View digest

Ascletis ASC30 Posters at ECO 2026: Once-Monthly Subcutaneous Depot Shows 7.5% Placebo-Adjusted Weight Loss at 16 Weeks

Ascletis announced multiple poster presentations at the 33rd European Congress on Obesity (ECO 2026) opening May 12 in Istanbul. ASC30, a first-in-class small-molecule GLP-1R fully biased agonist developed for once-daily oral and once-monthly to once-quarterly subcutaneous dosing, will be featured across formulation, PK, and clinical-data posters. The Phase 2 13-week study previously reported 7.7% placebo-adjusted weight loss at 60 mg oral dosing; the once-monthly subQ depot formulation achieved 7.5% placebo-adjusted weight loss at 16 weeks after three monthly doses, with topline T2D Phase 2 data expected Q3 2026. The subQ depot angle directly challenges Pfizer's MET-097i monthly thesis with a different mechanism (small-molecule GLP-1R biased agonist vs ultra-long-acting peptide).